Month: May 2025

Satellogic Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Revenue of $3.4 million in 1Q 2025 Domestication to U.S. Completed Awarded $30 Million Contract for AI-First Constellation and Closed $20 Million Registered Direct Offering NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, today provided a business update and reported its financial results for the three months ended March 31, 2025. “The year is off to a great start with our recent announcements in April related to our $30 million low latency, near-daily AI-first constellation contract, our sovereign defense and intelligence imagery sales to Brazil and Singapore, and the closing of a registered direct offering in which we received $20 million in gross proceeds, which further strengthened our liquidity position. These milestones, coupled...

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal Phase 3 clinical trial in early AD, with the first participants entering the study on February 5, 2025. The trial is currently in the process of activating clinical sites across the U.S. and enrolling patients with the goal of treating an estimated 760 participants with either buntanetap or placebo. This dual 6/18-month pivotal Phase 3 study will evaluate the symptomatic benefits of buntanetap...

Astrotech Reports Third Quarter of Fiscal Year 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2025, which ended March 31, 2025. Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer and Chief Technology Officer, said, “Our customizable, portable and field updatable mass spectrometry instruments have the potential to be a game changer in a growing list of large end markets such as airport security and cargo scanning, narcotics detection, environmental monitoring and chemical processing. I am very proud of our team’s accomplishments, as we now have launched four product lines that we believe will expand our sales opportunities to potential customers from around the world. We have been serving airports worldwide with 1st Detect’s...

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139 (semaglutide implant) for chronic weight management in obese and overweight patients Company plans to spin off Cortigent, Inc., a division that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company...

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

– Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile – Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended March 31, 2025, and provided business updates. “We are excited about the transformative potential of our AI-driven metagenomics platform across multiple indications...

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP) Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAP Granted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC)BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update. “The amezalpat program...

Global Star Acquisition Inc. and K Enter Holdings Inc. Finalize Business Combination

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

K Wave Media Ltd. Shares to Begin Trading on Nasdaq on May 14, 2025 Under Ticker “KWM” SEOUL and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Global Star Acquisition Inc. (NASDAQ: GLST) (“Global Star”), a special purpose acquisition company and K Enter Holdings Inc. (“K Enter”), a holding company with an internal K drama production team and controlling interest in six diversified entertainment operating companies based in Korea and engaged in the entertainment content and IP creation businesses, today announced the completion of the previously announced business combination that will result in the creation of K Wave Media Ltd. Accordingly, K Wave Media Ltd.’s ordinary shares and warrants are expected to commence trading on The Nasdaq Global Market under the symbols “KWM” and “KWMWW”, respectively on May 14, 2025. The business combination...

GEN Restaurant Group Announces First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) — GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of GEN Korean BBQ, a fast-growing casual dining concept with an extensive menu and signature “grill at your table” experience, is announcing financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial and Recent Operational Highlights Total revenue grew 13.0% year-over-year to $57.3 million for the first quarter. Restaurant-level adjusted EBITDA(1) increased 6.0% to $9.0 million compared to $8.4 million for the prior year period. Same-store sales were down a modest 0.7% to being down 5.6% for all of 2024. Opened six new locations in the first quarter, expanding total store count to 49 locations across eleven states. The Company remains on track to open 12 to 13 new stores in...

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates:In December 2024, Checkpoint announced that the U.S. Food and Drug Administration (“FDA”) approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery...

Evolution Petroleum Reports Fiscal Third Quarter 2025 Results and Declares Quarterly Cash Dividend for Fiscal Fourth Quarter

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Declares Quarterly Dividend of $0.12 for Fiscal Fourth Quarter 2025 HOUSTON, Texas, May 13, 2025 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced its financial and operating results for its fiscal third quarter ended March 31, 2025. Evolution also declared its 47th consecutive quarterly cash dividend of $0.12 per common share for the fiscal 2025 fourth quarter. Financial & Operational Highlights($ in thousands) Q3 2025 Q2 2025 Q3 2024 % Change vs Q3/Q2 % Change vs Q3/Q3 2025 YTD 2024 YTD % Change vs YTD’24Average BOEPD 6,667 6,935 7,209 (4 )% (8 )% 7,033 6,651 6 %Revenues $ 22,561 $ 20,275 $ 23,025 11 % (2 )% $ 64,732 $ 64,650 — %Net...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals